ArticleParkinsonism & related disorders2021
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity.
Article in Parkinsonism & related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effect of combined motor and cognitive rehabilitation on motor performance in Parkinson's disease: a systematic review and meta-analysis.Journal of rehabilitation medicine · 2026Pooled it
- Pooled it
- Smartphone-Based Multimodal Digital Biomarker Integration for Parkinson's Disease Screening and Diagnostic Support.Neurology and therapy · 2026Article
- Automatic and explainable assessment for Parkinson's disease by video-based human motion understanding.Journal of neuroengineering and rehabilitation · 2026Article
- Continuous assessment of daily-living gait using self-supervised learning of wrist-worn accelerometer data.NPJ digital medicine · 2026Article
- Sensor-Derived Parameters from Standardized Walking Tasks Can Support the Identification of Patients with Parkinson's Disease at Risk of Gait Deterioration.Bioengineering (Basel, Switzerland) · 2026Article
- The conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheses.Therapeutic advances in neurological disorders · 2026Review
- Assessing the Generalizability of Foundation Models for the Recognition of Motor Examinations in Parkinson's Disease.Sensors (Basel, Switzerland) · 2025Article
- [Commercial devices for monitoring symptoms in Parkinson's disease: benefits, limitations and trends].Revista de neurologia · 2024Review
- Characterization of Walking in Mild Parkinson's Disease: Reliability, Validity and Discriminant Ability of the Six-Minute Walk Test Instrumented with a Single Inertial Sensor.Sensors (Basel, Switzerland) · 2024Article
- Commercial symptom monitoring devices in Parkinson's disease: benefits, limitations, and trends.Frontiers in neurology · 2024Review
- Overview on wearable sensors for the management of Parkinson's disease.NPJ Parkinson's disease · 2023Review
- A Randomized Placebo-Controlled Study of a Transcranial Photobiomodulation Helmet in Parkinson's Disease: Post-Hoc Analysis of Motor Outcomes.Journal of clinical medicine · 2023Article
- Can Digital Mobility Assessment Enhance the Clinical Assessment of Disease Severity in Parkinson's Disease?Journal of Parkinson's disease · 2023Article
- Binaural acoustic stimulation in patients with Parkinson's disease.Frontiers in neurology · 2023Article
- Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform.JMIR human factors · 2022Article
- Parkinson's disease severity clustering based on tapping activity on mobile device.Scientific reports · 2022Article
- Stage-specific digital health technology biomarkers enhance diagnostic and early progression detection in Parkinson's disease.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionEmerging technologies show promise for enhanced characterization of Parkinson's Disease (PD) motor manifestations. We evaluated quantitative mobility measures from a wearable device compared to the conventional motor assessment, the Movement Disorders Society-Unified PD Rating Scale part III (motor MDS-UPDRS).
methodsWe evaluated 176 PD subjects (mean age 65, 65% male, 66% H&Y stage 2) during routine clinic visits using the motor MDS-UPDRS and a 10-min motor protocol with a body-fixed sensor (DynaPort MT, McRoberts BV), including the 32-ft walk, Timed Up and Go (TUG), and standing posture with eyes closed. Regression models examined 12 quantitative mobility measures for associations with (i) motor MDS-UPDRS, (ii) motor subtype (tremor dominant vs. postural instability/gait difficulty), (iii) Montreal Cognitive Assessment (MoCA), and (iv) physical functioning disability (PROMIS-29). All analyses included age, gender, and disease duration as covariates. Models iii-iv were secondarily adjusted for motor MDS-UPDRS.
resultsQuantitative mobility measures from gait, TUG transitions, turning, and posture were significantly associated with motor MDS-UPDRS (7 of 12 measures, p < 0.05) and motor subtype (6 of 12 measures, p < 0.05). Compared with motor MDS-UPDRS, several quantitative mobility measures accounted for a 1.5- or 1.9-fold increased variance in either cognition or physical functioning disability, respectively. Among minimally-impaired subjects in the bottom quartile of motor MDS-UPDRS, including subjects with normal gait exam, the measures captured substantial residual motor heterogeneity.
conclusionClinic-based quantitative mobility assessments using a wearable sensor captured features of motor performance beyond those obtained with the motor MDS-UPDRS and may offer enhanced characterization of disease heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.